Tab: Melphalan tablets are indicated in the treatment of: multiple myeloma; advanced ovarian adenocarcinoma.
Melphalan tablets may be used in the treatment of: breast carcinoma: melphalan either alone or in combination with other drugs has a significant therapeutic effect in a proportion of patients suffering from advanced breast carcinoma; polycythaemia rubra vera: melphalan is effective in the treatment of a proportion of patients suffering from polycythaemia vera.
Inj: ALKERAN Injection, administered by regional arterial perfusion, is indicated in the treatment of: localised malignant melanoma of the extremities; localised soft tissue sarcoma of the extremities.
ALKERAN Injection, at conventional intravenous dosage, may be used in the treatment of: multiple myeloma: ALKERAN Injection, either alone or in combination with other cytotoxic drugs, is as effective as the oral formulation in the treatment of multiple myeloma; advanced ovarian cancer: ALKERAN Injection produces an objective response in approximately 50% of the patients with advanced ovarian adenocarcinoma, when given alone, or in combination with other cytotoxic.
ALKERAN Injection, at high intravenous dosage, may be used in the treatment of: multiple myeloma: complete remissions have been achieved in up to 50% of patients given high-dose ALKERAN Injection, with or without haematopoietic stem cell rescue, either as first-line treatment or to consolidate a response to conventional cytoreductive chemotherapy; advanced neuroblastoma in childhood: high-dose ALKERAN Injection with haematopoietic stem cell rescue has been used either alone, or combined with radiotherapy and/or other cytotoxic drugs, to consolidate a response to conventional treatment.
A significant increase in the duration of disease-free survival was demonstrated in a prospective randomised trial of high-dose Alkeran injection versus no further treatment.